|Videos|August 24, 2016

Pharmacists & Veterinarians Partner Up to Oversee Antibiotic Use in Agriculture

Emily Heil, PharmD, BCPS-AQ ID, assistant professor at the University of Maryland School of Pharmacy, discusses how a new partnership between pharmacists and veterinarians will impact antimicrobial resistance.

Emily Heil, PharmD, BCPS-AQ ID, assistant professor at the University of Maryland School of Pharmacy, discusses how a new partnership between pharmacists and veterinarians will impact antimicrobial resistance.

Interview Transcript (slightly modified for readability).

“I think the relationship between pharmacists and veterinarians is relatively new and this is going to be a really interesting area to see how it develops. Veterinarians are going to be so much more heavily involved with the use of antibiotics in agriculture, thanks to the Veterinary Feed Directive that’s going live in January.

I think as pharmacists we can really help provide some education to our veterinary colleagues about why this issue is so important because they might not realize how the antimicrobial resistance crisis is really affecting human medicine because they don’t see that side of practice. So, we can work with our veterinary colleagues, to educate them about why their new role in providing oversight into how antibiotics [are] used in agriculture can be so important on the human health end.

I think it’s going to be a really beneficial partnership to work together because veterinarians will now have to use pharmacies to handle those antibiotic prescriptions, so I think it just provides a lot of opportunity for education both ways and its really new territory for both professions that traditionally have not had a lot of overlap and interactions.”


Related to this article

Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.